An evaluation of the diagnosis and treatment of chordoma

ROBERT P. KAMRIN, THE LATE JOHN N. POTANOS, AND J. LAWRENCE POOL

From the Department of Neurological Surgery, Columbia University
College of Physicians and Surgeons, and The Neurological Institute of New York

Improved methods of diagnosis have indicated that chordoma more frequently affects the central nervous system than was previously suspected. For example, in a large neurosurgical service, one can now expect to see one or two cases a year. The world literature in 1960, derived mostly from isolated case reports, mentioned 548 cases of chordoma in the following locations: 240 intracranial, 81 vertebral, and 227 sacrococcygeal (Forti and Venturini, 1960). Few large series, however, have been published from single institutions (Dahlin and MacCarty, 1952; Poppen and King, 1952; Congdon, 1952). This paper presents all histologically confirmed cases of chordoma, 30 in number, seen at the Columbia Presbyterian Medical Centre since 1927.

MATERIAL

The 30 cases of chordoma discussed in this report have all been histologically verified by biopsy and five have in addition been confirmed by necropsy. Sixteen of these cases were diagnosed on clinical grounds since 1950. After diagnosis, all these patients were treated by surgery and/or radiotherapy.

DISTRIBUTION

Chordomas are classified according to their origin from intracranial, vertebral, or sacrococcygeal sites. A separation of the intracranial group into those arising from the clivus and those arising elsewhere in the cranium, however, is not useful clinically because of the marked overlapping of symptoms.

Early reviews noted a preponderance of sacrococcygeal chordomas; more recent studies have shown chordomas to be equally divided between intracranial and sacrococcygeal locations (Faust, Gilmore, and Mudgett, 1944; Forti and Venturini, 1960; Zoltán and Fényes, 1960). The vertebral group accounts for only 15% of all these tumours, their distribution being cervical, lumbar, and thoracic in decreasing order of frequency. The median age of onset of symptoms is the middle thirties for intracranial chordoma and middle fifties for other chordomas. Males outnumber females 3:1 (Dahlin and MacCarty, 1952).

Our cases differ from other series in distribution, 16 being intracranial, nine vertebral (four cervical, one thoracic, four lumbar), and five sacrococcygeal. The age of onset varied from the post-pubertal years to the eighth decade (Table I). The age distribution of the present series confirms that whereas vertebral and sacrococcygeal tumours most often appear after the age of 50, it is not rare to find that chordomas become symptomatic in the second decade. This was also noted by Mabrey (1935) who found 13% of intracranial chordomas occurring before the age of 20 and 25% before age 30 years. The high incidence of chordoma in males was also noted in our series: 22 males and only eight females.

TABLE I

<table>
<thead>
<tr>
<th>AGE AT ONSET OF SYMPTOMS</th>
<th>Years</th>
<th>Cranial</th>
<th>Cervical</th>
<th>Thoracic</th>
<th>Lumbar</th>
<th>Sacrococcygeal</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-9</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>10-19</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>20-29</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>30-39</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>9</td>
<td></td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>40-49</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td></td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>50-59</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>5</td>
<td></td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>60-69</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>70-79</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30</td>
</tr>
</tbody>
</table>

CLINICAL COURSE

INTRACRANIAL Symptoms were usually present for one year before the patient was admitted to hospital for study (Table II). The most frequent symptoms of onset were headache of a generalized nature and/or a visual disturbance. The most common visual complaint was diplopia although decreased visual acuity or ptosis have also been reported (Table III).

157
Robert P. Kamrin, the late John N. Potanos, and J. Lawrence Pool

TABLE II
LENGTH OF SURVIVAL AND THERAPY OF TUMOUR

<table>
<thead>
<tr>
<th>Tumour Site</th>
<th>Survival from Onset of Symptoms</th>
<th>Survival from Start of Therapy</th>
<th>Type and Amount of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intracranial</td>
<td>2 yr.</td>
<td>4 days</td>
<td>Subtotal removal</td>
</tr>
<tr>
<td></td>
<td>3 yr.</td>
<td>2 yr.</td>
<td>Total removal, 4,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>3 yr.</td>
<td>2 yr.</td>
<td>Biopsy, 3,600r tumour dose</td>
</tr>
<tr>
<td></td>
<td>18 mth.</td>
<td>6 mth.</td>
<td>Subtotal removal, 5,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>3 yr.</td>
<td>1 yr.</td>
<td>Subtotal removal</td>
</tr>
<tr>
<td></td>
<td>13 yr.</td>
<td>11 yr.</td>
<td>Subtotal removal, 16,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>15 yr.</td>
<td>14 yr.</td>
<td>Biopsy, 17,500r tumour dose, radium, chemotherapy</td>
</tr>
<tr>
<td></td>
<td>2 yr.</td>
<td>1 yr.</td>
<td>Subtotal removal</td>
</tr>
<tr>
<td></td>
<td>8 yr.</td>
<td>7 yr.</td>
<td>Subtotal removal, 9,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>4 yr.</td>
<td>2 yr.</td>
<td>Subtotal removal, 4,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>5 yr.</td>
<td>4 yr.</td>
<td>Subtotal removal, 4,800r tumour dose</td>
</tr>
<tr>
<td></td>
<td>6 yr.</td>
<td>5-5 yr.</td>
<td>Biopsy, 13,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>1 yr.</td>
<td>6 mth.</td>
<td>Biopsy, 6,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>5 yr.</td>
<td>4 yr.</td>
<td>Biopsy, 4,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>4 yr.</td>
<td>2 yr.</td>
<td>Biopsy, 5,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>4 yr.</td>
<td>2 yr.</td>
<td>Biopsy, 4,000r tumour dose, chemotherapy</td>
</tr>
<tr>
<td>Cervical</td>
<td>9 yr.</td>
<td>8 yr.</td>
<td>Biopsy, 10,500r tumour dose</td>
</tr>
<tr>
<td></td>
<td>3 yr.</td>
<td>2 yr.</td>
<td>Subtotal removal, 4,200r tumour dose</td>
</tr>
<tr>
<td></td>
<td>17 yr.</td>
<td>16 yr.</td>
<td>Subtotal removal</td>
</tr>
<tr>
<td></td>
<td>4 yr.</td>
<td>2 yr.</td>
<td>Biopsy, 6,000r tumour dose</td>
</tr>
<tr>
<td>Thoracic</td>
<td>3 yr.</td>
<td>2 yr.</td>
<td>Subtotal removal, 6,000r tumour dose</td>
</tr>
<tr>
<td>Lumbar</td>
<td>2 yr.</td>
<td>1 yr.</td>
<td>Subtotal removal, 6,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>8 yr.</td>
<td>4 yr.</td>
<td>Subtotal removal, 5,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>14 yr.</td>
<td>8 yr.</td>
<td>Total removal, 4,000r tumour dose</td>
</tr>
<tr>
<td></td>
<td>4-5 yr.</td>
<td>4 yr.</td>
<td>Biopsy, 8,600r tumour dose</td>
</tr>
<tr>
<td>Sacrococcygeal</td>
<td>3 yr.</td>
<td>2 yr.</td>
<td>Total removal, radiation (dose unknown)</td>
</tr>
<tr>
<td></td>
<td>5 yr.</td>
<td>4 yr.</td>
<td>Subtotal removal</td>
</tr>
<tr>
<td></td>
<td>2 yr.</td>
<td>1 yr.</td>
<td>Total removal</td>
</tr>
<tr>
<td></td>
<td>7 yr.</td>
<td>5 yr.</td>
<td>Biopsy, 6,100r tumour dose</td>
</tr>
<tr>
<td></td>
<td>5 yr.</td>
<td>2 yr.</td>
<td>Biopsy, radiation (dose unknown)</td>
</tr>
</tbody>
</table>

1Patient alive or was alive when lost to follow-up.

TABLE III
PREDOMINANT PRESENTING SYMPTOMS OF INTRACRANIAL CHORDOMA

<table>
<thead>
<tr>
<th>Present Series</th>
<th>Mayo (1960)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>Number</td>
</tr>
<tr>
<td>Headache</td>
<td>14 (87%)</td>
</tr>
<tr>
<td>Diplopia</td>
<td>12 (75%)</td>
</tr>
<tr>
<td>Blurred vision</td>
<td>4 (25%)</td>
</tr>
<tr>
<td>Visual field defect</td>
<td>6 (38%)</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>4 (25%)</td>
</tr>
<tr>
<td>Endocrine dysfunction</td>
<td>3 (19%)</td>
</tr>
<tr>
<td>Anosmia</td>
<td>1 (6%)</td>
</tr>
<tr>
<td>Posis</td>
<td>3 (19%)</td>
</tr>
<tr>
<td>Decreased hearing</td>
<td>4 (25%)</td>
</tr>
</tbody>
</table>

Although it was rare for a patient to report a visual field defect, the latter was often found on testing. The development of headaches and visual disturbance usually paralleled each other in onset and progression. Additional symptoms reported in order of decreasing frequency were dysphagia, decreased hearing, endocrine disturbance manifested by impotence in the male and amenorrhea in the female, and anosmia.

As to signs, 90% of our patients had an extracocular palsy, most often due to sixth nerve involve-
with intracranial lesions (Figs. 1 and 2). In 10 cases, destruction and infiltration of the sphenoid bone and sinus were noted. Destruction of the clinoid processes was present in nine patients and of the petrous ridge in three. Suprasellar calcification was observed in 30% of cases.

Contrast studies such as arteriography or air encephalography always revealed superior and posterior displacement of the third ventricle and aqueduct, while some degree of aqueductal obstruction was often present leading to slight dilatation of the third and lateral ventricles (Fig. 3). No patients

in this series, however, had sufficient aqueductal blockage to cause papilloedema even though the chiasmal and interpeduncular cisterns were usually obliterated. Superior and lateral displacement of the suprachiasmatic portion of the internal carotid artery and of the anterior and middle cerebral arteries was often present. No tumour stains or abnormal vessels were seen. In a word, extensive suprasellar, parasellar, and often intrasellar tumour masses could be demonstrated by appropriate contrast studies.

Eleven patients had been closely followed for longer than one year. In seven symptoms had progressed within this period following therapy. The
average time until evidence of recurrence was 11 months. In our total series of intracranial chordoma, the average time of survival at this time was 43 months (3-6 years) following surgical and/or radiation therapy, or 56 months (4-7 years) from the onset of symptoms. In contrast, in untreated intracranial chordoma, the average survival time from onset of symptoms was 28-8 months (Mabrey, 1935). Of the 16 patients in this series, six were able to return to normal activities in school or work after initial treatment, although at this time no patient is thought to be free of tumour.

**CERVICAL** All four patients noted pain as their initial symptom. In three the pain was localized to the posterior neck, and in the fourth, the initial pain was in the mastoid region. Further progress of the disease resulted in increasing pain spreading to the arms and shoulders in two patients and the appearance of a mass in the other two patients. The masses were retropharyngeal in one patient and 'pre-auricular' in the other. Generally, symptoms were present for one year before admission to hospital was advised.

On examination, three of the four patients had palpable masses, one being an asymptomatic retropharyngeal mass. Two patients demonstrated long tract signs with weakness and decreased sensation in the lower extremities. Laboratory studies were normal except for a markedly elevated cerebrospinal fluid protein level of 260 mg. % in the patient with severe lower extremity dysfunction and a slight protein elevation in a second patient.

Radiography revealed pharyngeal soft tissue masses in three patients. Bony erosion was noted in two patients with collapse of the second cervical body in one. The bony lesions were found in the high cervical region, above the fourth cervical body. Myelography was performed on only one patient in whom a partial block was demonstrated by lumbar puncture.

Symptoms recurred within one year in 75% of these patients. The average time of survival, regardless of method of treatment, was seven years from the time of diagnosis and treatment and eight years from the onset of symptoms (Table II). In general, the greater the degree of spinal cord involvement, the shorter the prognosis. When marked long tract signs were present, total incapacity and death occurred within one year. No confirmed cure of such lesions at this site has been reported.

**THORACIC** There was only one patient with a lesion at the thoracic level in our series and indeed, tumours of this region have been rare. The presenting symptom was local pain. A radicular component was noted when root encroachment later occurred.

Two years elapsed between onset of symptoms and therapy of this tumour and this time lag appears consistent with reports in the literature (Rosenqvist and Saltzman, 1959). Other symptoms which these authors reported included decreased sensation and strength in the lower extremities, while examination usually revealed long tract signs with pathological reflexes and motor and sensory impairment below the lesion. Laboratory studies were reported as normal except for elevation of the cerebrospinal fluid protein which, in our patient, was 594 mg. % associated with a complete cerebrospinal fluid block. This is again consistent with reports in the literature, as partial or complete block was usually found by the time the patient was first admitted to hospital. Radiography in our patient revealed increased density of the involved vertebra, without collapse, and definition of a soft tissue mass. Vertebral collapse and osteolytic lesions are, however, as frequently present as are the findings just described (Windeyer, 1959).

Since this tumour cannot be completely removed, the time of recurrence will depend mainly on the major direction of growth of the tumour. In our case, the patient was well and at work for two years following decompressive laminectomy and radiation therapy (Table II). He was then lost to follow-up. In general, the lesion will be fatal within six years of the onset of symptoms (Baker and Coley, 1953).

**LUMBAR** Pain was the presenting symptom in all four cases of lumbar involvement in our series. This symptom was present as long as six years in one patient and four years in a second before the definitive diagnosis was established. Later symptoms were those of cauda equina compression or nerve root irritation. Two patients presented with urinary incontinence and decreased sensation and weakness of the legs. The other two patients had a clinical history suggestive of a herniated nucleus pulposus with shooting pains in a lower lumbar dermatomal distribution and appropriate weakness and sensory impairment. Examination was compatible with a cauda equina syndrome with decreased deep tendon reflexes and impairment of sensation. Laboratory studies were normal except for minimal elevations in the cerebrospinal fluid protein to 50 to 60 mg. % in the two patients with signs of limited root irritation. Marked elevation of cerebrospinal fluid protein was present in the two patients having signs of cauda equina compression.

Radiography revealed pedicle erosion and widening of intervertebral foramina in two patients, collapse of a vertebral body in one, and increased bone density with some radiolucent areas in the last. Similar changes have been previously described.
in the literature (Allen, 1955; Sennett, 1953; Windeyer, 1959).

Recurrence of tumour was noticed in all patients within one year of combined operative and radiation therapy. Though one patient has been symptom free for seven years following a second course of radiotherapy, it is doubtful if any is free of tumour. Survival has been reported to be less than six years from the onset of symptoms (Baker and Coley, 1953). To this time, average survival has been seven years from the onset of symptoms and four years from the time of initial diagnosis and therapy in this group of patients, of whom one died 4.5 years after the onset of symptoms and only one is back at work (Table II).

SACROCCYGEAL Pain in the rectum was the presenting symptom in four of five patients with sacrococcygeal chordoma. This was present for six months to one year before hospital admission and diagnosis. In the fifth patient, an asymptomatic posterior sacral mass was present for three years before diagnosis and therapy. Additional symptoms noted in all patients before admission to hospital were perirectal, buttock, or thigh pain, or disturbed sensation and sphincter disturbance, usually constipation and/or incontinence. On examination, all patients had a retro-rectal mass which lay beneath the rectal mucosa but did not penetrate it. In addition, two patients had saddle anaesthesia. Laboratory studies were always reported within normal limits.

Radiography revealed destructive or radiolucent areas in the sacrum and coccyx (Fig. 4). No osteoblastic areas were noted nor was widening of the spinal canal observed (Hsieh and Hsieh, 1936). Barium enema examination showed the rectum and sigmoid colon to be displaced anteriorly.

The tumour recurred after therapy within one year in four of five cases. The average survival time from onset of symptoms has been five years; survival from time of therapy has been three years (Table II). Survival from the time of onset of symptoms has been reported to be one to six years but survival for longer periods has not been unusual (Faust et al., 1944). Only one patient has returned to work following therapy of such tumours at this site.

FIG. 4. Radiograph of a 54-year-old man with pain in the sacrum for one and a half years. A rectal mass was present. The radiograph demonstrates expansion of the sacrum with destruction and rarefaction of bone.

DIAGNOSIS

The diagnosis of chordoma can rarely be made on clinical grounds alone. By combining the clinical picture with radiographic findings, however, a diagnosis of chordoma may be strongly suspected.

The intracranial chordomata can be divided clinically into two groups: those in a parasellar location affecting cranial nerves 1 through 7 and those chordomas of the clivus which involve the eighth through twelfth cranial nerves and often the upper cervical spinal cord. Cases of the former group generally present with a triad of headache, visual disturbances, and diplopia (Givner, 1945; Meaney, Greenwald and Phalen, 1956; Moya, 1960). Givner (1945) states: 'Unexplained paralysis of the lateral rectus muscle... in a patient in his thirties with progression to chiasmatic signs, headaches preceding defects of the visual fields and no evidence of disorder of the pituitary should suggest chordoma'.

Symptoms of impotence, loss of libido, or disordered menstruation were present in 10 to 20% of cases. Papilloedema and optic atrophy are seen with equal frequency, being present in 20% of cases (Givner, 1945). No patient in our series presented with papilloedema although four had optic atrophy.

On radiographic examination, erosion of the clinoideal processes, destruction of the sphenoid wing, and enlargement of the sella turcica were most often seen with destruction of some part of the sella in 70%
of cases (Utne and Pugh, 1955). Suprasellar calcification is present in from 30 to 75% of cases (Halper, 1949; Moya, 1960; Wood and Himadi, 1950). If sphenoid sinus involvement was present, biopsy of the sinus usually led to a positive diagnosis (Dahlin and MacCarty, 1952).

Of the special radiographic studies, gas encephalography generally proved more helpful than arteriography since these tumours arise from the midline. Gas encephalography will demonstrate posterior and superior displacement of the aqueduct and third ventricle with non-filling of the anterior portion of the third ventricle (Utne and Pugh, 1955; Wood and Himadi, 1950). This was found in all of our gas encephalograms and in 90% of those reported by Moya (1960). In addition, ventricular dilatation was present in 20% of the patients studied.

In the predominately clival chordoma, presenting symptoms were those of a tumour of the cerebellopontine angle, some cases also having cervical spinal cord involvement. Decreased hearing, dysphagia, tongue deviation, and neck pain were common presenting symptoms. In our series, a pharyngeal mass, most often symptomatic, was present in 65% of patients with lower cranial nerve signs. Such a mass should always be sought in the presence of lower cranial nerve dysfunction. If a mass can be seen, persistent attempts at biopsy will usually result in a positive tissue diagnosis. It was our experience that several attempts at biopsy were often necessary as the tumour does not invade the mucosa but lies deep in the pharyngeal wall, pushing normal structures before it as it grows out from the cervical spine. On radiographic examination, destruction of the clivus and a soft tissue retropharyngeal mass were often seen (Windley, 1959; Wood and Himadi, 1950). Involvement of the upper cervical vertebrae was not rare, making it difficult to decide whether a predominantly cervical or intracranial tumour was present.

The differential diagnosis, of course, depends on the location of the tumour. One must consider chromophobe adenoma, craniopharyngioma, suprasellar or clival meningioma, neurinoma, and nasopharyngeal carcinoma. Except for the last named neoplasm, extracranial extension of the tumour will aid in ruling out the other lesions.

In cervical chordomas, findings are those of a pharyngeal mass and/or of cervical spinal cord compression. All of our patients presented with neck pain and three of four with a palpable mass in the neck. The combination of dysphagia and cervical pain should suggest the diagnosis (Toole and Ioannovich, 1960). On radiographs, one sees an irregular lytic lesion of the involved bodies with preservation of the disc space. A soft tissue mass is usually present. The differential diagnosis must include metastatic tumour, tuberculous osteomyelitis and abscess, neurofibroma and meningioma (Sennett, 1953).

The thoracic chordoma is unlikely to give any specific signs clinically or radiologically of its identity. Symptoms of spinal cord compression, such as pain, lower extremity weakness, and sphincter disturbance, are seen. Radiological examination shows an osteolytic lesion with an adjacent soft tissue mass. If no soft tissue mass is present, the radiological appearance of the vertebra may mimic an angiomatous process. The major differential diagnoses are metastatic tumour, haemangioma, myeloma, chordroma, and giant cell tumour (Sennett, 1953).

Lumbar chordomas demonstrate clinical and radiographic findings identical with those of the thoracic group (Baker and Coley, 1953; Morris and Rabinovitch, 1947; Sennett, 1953). Though neither the lumbar nor thoracic areas are common sites for chordoma, the former site is involved twice as frequently as the latter.

Sacrococcygeal chordoma will present with pain or a mass, usually both being present. If a sacral mass presents posteriorly, however, no pain will be felt. Disturbance of sphincter control, most often constipation, is also common. In our series, all patients presented with pain, sphincter disturbance, and a palpable retro-rectal mass. Twenty-nine of 32 patients presented with pain and 50% with either a mass or sphincter disturbance in the series of Dahlin and MacCarty (1952). Other symptoms of weakness, paraesthesias, and numbness were less constant, being present in less than 20% of patients. On examination, the most constant finding is a mass (Dahlin and MacCarty, 1952; Gentil and Coley, 1948). When the mass presents anteriorly, it may displace the rectum or bladder, although invasion of the mucosa of these organs has not yet been reported. Other findings are related to the degree of nerve root involvement found. This tumour has been reported in patients as young as 2 years (Montgomery and Wolman, 1933). In Mabrey's (1935) collected series of 85 sacrococcygeal chordomas, four patients were below the age of 9 years.

The distinctive radiological findings of sacrococcygeal chordoma have been described by Hsieh and Hsieh (1936). These are expansion of the sacrum in which it appears widened in one or more diameters; rarefaction or destruction of bone; trabeculation; and calcifications. Erosion of bone was found on radiographs in 80% of our cases. Previous studies have noted osteolytic lesions in at least 75% of patients (Utne and Pugh, 1955).

The differential diagnosis of this tumour includes...
An evaluation of the diagnosis and treatment of chordoma

all of the presacral tumours (Castro, 1961). Of those causing pain, bone erosion, and a palpable mass, the most common lesions are metastatic tumour, sarcoma, tuberculous osteomyelitis, bone tumours, and anterior meningocoeles. On histological study of the removed tumour, mucoid carcinoma of the rectum or sigmoid has been reported as frequently being misdiagnosed as chordoma. We have a further tumour, a hypernephroma, which was repeatedly diagnosed as chordoma until necropsy revealed its true origin. This tumour presented in the lumbo-sacral region and exhibited all of the clinical and radiographic characteristics of chordoma. Two laminectomies were performed, adequate pathological specimens being taken each time. A diagnosis of chordoma as thought to be represented by a typical histological picture was returned on both occasions. Thus, we must caution against confusing hypernephroma as well as mucoid carcinoma with chordoma.

PATHOLOGY

The microscopic recognition of chordoma is sufficiently well known not to demand discussion here. A description of macroscopic pathology encountered at operation, however, is essential in order to evaluate the modes of treatment offered for this tumour.

There has not been a case reported of total removal of an intracranial chordoma. Embryological studies of the notochord in the base of the skull have demonstrated that the notochord traverses bony structures to lie both on the dorum sellae intracranially and against the basilar portion of the occipital bone extracranially (Gardner and Turner, 1941; Sensenig, 1956). Neoplastic change of the notochord thus gives rise to a midline tumour which may grow up into the base of the brain or down into the sphenoid sinus or into the nasopharynx. The tumour is unencapsulated or has a pseudo-capsule and invades both dura and bone with facility.

When seen at operation, the tumour has usually grown more to one side than another causing predominantly unilateral symptoms. Rather than presenting as a single large mass, several lobules of tumour connected by small bridges of tumour tissue are seen. The basilar cisterns are collapsed by the upward growth of the tumour and the third ventricle, pons, and aqueduct are pushed upward and backward. Thus, hydrocephalus is most often due to a combination of aqueductal compression and collapsing of the basilar absorbing surfaces making external decompression the only means of achieving reduction of increased intracranial pressure.

Since the intracranial portion of the chordoma starts at the dorsum sellae, it may follow a pathway of growth predominately into the middle and anterior fossae or into the posterior fossa. Anterior growth will cause dysfunction of the hypophysis and upper cranial nerves by direct tumour growth to and around these structures. Posterior growth will mainly affect the lower cranial nerves.

It has previously been noted that most patients with intracranial chordoma have a sixth nerve palsy (Givner, 1945). The reason for this is evident when one considers that the sixth nerve must course over the greatest bulk of the tumour to reach its foramen of exit.

At necropsy, the tumour is seen to grow as a sheet of cells over the floor of the middle or posterior fossa with many large lobules arising from this sheet. The tumour is noted to surround completely nerve and vascular structures rather than push them aside. Thus, anteriorly, the intracranial carotid artery is buried within the tumour while the cavernous sinus, being a more rigid structure, is invaded by tumour. When removal of the tumour is attempted, parts of it are found to be soft and to yield to suction easily; other parts are highly vascular or solid and are not amenable to this form of removal.

The chordoma often has a massive retropharyngeal component and when first seen appears to be a tumour only of the nasopharynx. The tumour, however, when traced posteriorly will be seen to arise from the base of the skull or the cervical vertebrae. At the time of necropsy, an intracranial or intraspinal extension of the tumour is always noted. Thus, total removal of these nasopharyngeal chordomas is impossible.

In the vertebral region, the chordoma surrounds the spinal cord, resembling a metastatic tumour, and causes compression within the bony canal. The tumour's growth, however, may be as extensive anteriorly into the retropleural or retroperitoneal space as it is posteriorly. Our series included several cases in which the surgeon believed that total removal of the tumour had been accomplished only to find recurrence within one year. This is understandable in the light of the gross pathology. Since whatever notochordal remnants the chordoma arises from are present within the body of the vertebra or disc, rather than external to them, it is evident that simple removal of tumour from around the spinal dura cannot effect total removal.

At necropsy, the chordoma can be seen infiltrating the vertebral body and growing anteriorly into the paraspinal tissues or posteriorly to surround the spinal cord. Once within the spinal canal, growth up or down the canal may occur.

The pathological findings in the sacrococcygeal chordoma present a separate problem from those...
encountered elsewhere in the skeletal axis. The
tumour arises from the lower bony sacrum and
grows out freely beneath the skin posteriorly or
below the peritoneal reflection anteriorly. Since
removal of the locally involved structures can be
accomplished without danger to life, radical excision
of the sacrum, coccyx, and adjacent soft tissue
structures can be attempted. Both at operation and
at necropsy, however, sheets of tumour cells are
often seen growing a considerable distance rostrally
in the sacral canal. This must be carefully watched
for, since these cells can easily escape notice and yet
form a nidus for a rapid recurrence of tumour.

Attempts at discrete removal of extradural
tumour alone must be unsuccessful because of the
constant infiltration of the tumour into the sacrum.
A punched-out area composed solely of fragmented
bone and tumour will usually be found within the
sacrum. Thus, because its location allows radical
excision, sacrococcygeal chordoma is the only type
that may be removed totally.

Another facet of chordoma growth is the presence
of metastases. Though metastases occur not
infrequently from sacrococcygeal chordoma, there
are isolated reports of metastases from other parts of
the neuraxis (Faust et al., 1954; Gentil and Coley,
1948; Graf, 1944; Greenwald, Meaney, and Hughes,
1957; Güthert and Henkel, 1941; Mabrey,
1935; Maynard, 1953; Morris and Rabinovitch,
1947; Schneegans and Mandigas, 1938; Toole and
Ioannovich, 1960; Uhr and Churg, 1949). Spread
from the sacrococcygeal region has been reported to
the peritoneum, lymph nodes, liver, lung, and pleura.
Of the seven reported cases of metastases from
chordoma outside of the sacrococcygeal region, two
have been from intracranial chordoma, both
spreading to the lung but one to the heart as well,
one from the cervical region to the lung, one from
the thoracic region to the lung, and three from the
lumbar region. Spread from the lumbar region has
been to the lung and in one case to the brain and
pancreas as well.

Three patients in our series demonstrated meta-
stases, one each from intracranial, cervical, and
sacrococcygeal locations. In the first two cases,
metastases were to the lung only whereas the sacro-
coccygeal tumour spread to the liver, lymph nodes,
skin, and lung. It is of interest that the patients with
intracranial and cervical chordomas survived 15 and
nine years respectively and both received radio-
therapy in excess of 10,000r tumour dose. The patient
with a sacrococcygeal chordoma received 6,100r
tumour dose and survived for seven years. That the
two factors of long survival and massive radiation
may have enhanced tumour spread must be con-
sidered.

With the realization that total removal of a chordoma
cannot be performed except occasionally in the
sacrococcygeal region, therapy must be directed
toward surgical decompression of vital structures
followed by radiation (Dahlin and MacCarty, 1952;
Hass, 1934; Rosenvist and Saltzman, 1959;
Sennett, 1953). Radiotherapy is administered as
palliation and can result in regression of tumour and
relief of pain.

An evaluation of different methods of therapy in
the largest series of patients treated at one institution
concludes that a combination of surgery and radio-
therapy offers the best chance of prolonging survival
(Dahlin and MacCarty, 1952). Unfortunately, the
number of patients in each therapeutic category is
too small to indicate anything more than a trend.

Analysis of the rationale for surgical intervention
must again be separated into the intracranial and
vertebral groups. In intracranial tumours, if a
diagnosis can be established by pharyngeal or
sphenoid sinus biopsy, operation would be indicated
only for decompression of the optic nerves when
blindness is threatened or for performance of an
external shunting procedure for relief of hydro-
cephalus. If the diagnosis has not yet been established
pre-operatively, some operative procedure to ascer-
tain the diagnosis would be indicated.

In the vertebral regions, rapidly impending para-
plegia would constitute the only indication for
surgical intervention other than for biopsy purposes,
though biopsy alone could probably be performed
by percutaneous biopsy of the involved vertebra. At
post-mortem examination in a case of cervical
chordoma, we noted focal areas of degeneration in
the lateral and posterior columns though actual cord
compression was not marked. This was presumably
the effect of vascular compromise and the thought
that operation may accomplish only further de-
crease of an already marginal blood supply must be
kept in mind.

One series of 18 patients with radical sacrectomy
for sacrococcygeal chordoma has already been
reported (MacCarty, Waugh, Coventry, and
O'Sullivan, 1961). In a follow-up period of as long
as 12 years, but averaging six years, 12 patients are
still alive, seven without recurrence. In addition to
operation, 13 patients received post-operative
radiotherapy. No report has been made on post-
operative morbidity but of the first eight patients
reported, only one was noted to have returned to
work (MacCarty, Waugh, Mayo, and Coventry,
1952).

In our patients, the dose of radiation has been
steadily increased over the years so that a 3,000 to
An evaluation of the diagnosis and treatment of chordoma

5,000r tumour dose will be given as the initial treatment dose and doses of 2,000 to 3,000r tumour dose repeated as often as recurrence is noted (Table II). It is our feeling that tumour doses greater than 5,000r cause more prolonged remission than smaller doses. This trend toward higher radiation doses is noted in the literature also. Ormerod (1960) reported a case of intracranial chordoma receiving 6,175r tumour dose with radiographic evidence of disappearance of tumour. Tumour reappeared on the opposite side in one and a quarter years and was treated with 4,175r tumour dose with disappearance of the second tumour. The patient was well without recurrence four years later. Friedman (1953) has treated a lumbar chordoma with 7,200r tumour dose by rotational methods and has noted no recurrence in one year.

Other methods of treatment reported in the literature have been intracranial implantation of irradiated materials and chemotherapy (McSweeney and Sholl, 1959; Zoltán and Fényes, 1960). In two of our patients, intracarotid perfusion of the chemotherapeutic agent, methotrexate, was followed by death in eight days in one patient and evidence of recurrence of tumour in the other patient within one year.

At present, our plan of therapy consists of establishment of diagnosis by the simplest means of biopsy followed by large radiation doses to the tumour, 5,000r tumour dose or greater. We reserve surgical therapy only for acute problems which may be handled in no other way. This means of therapy has not been followed for sufficient time to evaluate its benefits.

CONCLUSIONS

Thirty cases of chordoma seen at the Columbia Presbyterian Medical Centre since 1927 are reviewed and a rationale for treatment offered. Sacrococcygeal chordoma is the only type amenable to complete excision and thus should be treated surgically. Cases of intracranial and vertebral chordoma should be biopsied by closed or open methods for confirmation of diagnosis, then given large tumour doses of therapeutic radiotherapy. Except for emergency situations demanding surgical decompression for the preservation of life or of vital structures, surgical treatment of non-sacrococcygeal chordoma has little to offer.

REFERENCES

An evaluation of the diagnosis and treatment of chordoma

Robert P. Kamrin, The Late John N. Potanos and J. Lawrence Pool

*J Neurol Neurosurg Psychiatry* 1964 27: 157-165
doi: 10.1136/jnnp.27.2.157

Updated information and services can be found at:
http://jnnp.bmj.com/content/27/2/157.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/